MedicalResearch.com Interview with:
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Clinical trials in early prostate cancer take more than a decade to report on.
Multiple early reporting endpoints have been proposed, but which one is best, remains unknown, until now. Of all the possible early endpoints examined, to date, how low a PSA blood test falls to, after treatment with radiation and hormonal therapy, appears to be the best, specifically, if the PSA doesn’t get below half a point, that patient is very likely to die of prostate cancer if given standard treatment for recurrence.
Those men deserve prompt enrollment on clinical trials in order to properly save their life.
MedicalResearch.com: What should readers take away from your report?
Response: This study’s results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: This newly defined endpoint, based on the PSA blood test, can be used to promptly enroll men today on clinical trials whose hope is to take a prostate cancer that appears to be aggressive and incurable and make it curable.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Royce TJ, Chen M, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D’Amico AV. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation TherapyA Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. Published online January 12, 2017. doi:10.1001/jamaoncol.2016.5983
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.